With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returns as the only meeting spotlighting the latest developments in target identification, selection and target specific ADC development that will continue progressing first- and best-in-class ADCs into and through the clinic.

Providing a greater focus on identifying and validating novel targets such as SEZ6, re-examining what makes a good target, and analyzing how novel linker-payload technologies such as topoisomerase I payloads are changing the target selection paradigm; this is your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.

Join 100+ of your peers from  Iksuda Therapeutics, Merck &Co, Angiex, Ziel Bio, and Seagen; working in discovery, biology, target identification and validation. With three days of content carefully created to provide you with renewed strategic and scientific insights to progress your ADC pipelines for 2024 and beyond, this is a conversation not to miss.